EXPERIMENTAL STUDY OF THE TOXICITY AND HAZARD OF QUETIAPINE FUMARATE

Cover Page

Cite item

Full Text

Abstract

Quetiapine is a psychotropic drug, a dibenzothiazepine derivative and a representative of the class of neuroleptics (antipsychotic drugs) of a new subgroup – atypical antipsychotic drugs («second-generation antipsychotics»). Quetiapine fumarate belongs to the 3rd hazard class in terms of DL50 when administered in the stomach according to GOST 12.1.007-76 (DL50 1380-1680 mg/kg, mice and rats), has a local irritant effect: pronounced - on the mucous membrane of the eyes and moderately pronounced - on the skin. There are no signs of skin resorptive or cumulative effects of quetiapine fumarate. When inhaled, an aerosol of quetiapine fumarate has a general toxic and irritating effect in rats. The threshold of acute inhalation action of quetiapine fumarate is set at 6,2 mg/m3 for general toxic effect (effect on the quantitative composition of peripheral blood and the cardiovascular system) and irritating effect on the mucous membranes of the upper respiratory tract. For quetiapine fumarate, the tentative safe exposure level in the air of the working area is recommended at 0,2 mg/m3 , aerosol, with «+» - special protection of the skin and eyes is required. The tentative safe exposure level in the atmospheric air of urban and rural settlements is 0,002 mg/m3.

About the authors

M. I. Golubeva

All-Union Scientifi c Center for the Safety of Biologically Active Substances

Author for correspondence.
Email: golubevamargo@mail.ru

Golubeva Margarita Ivanovna

142450, Staraya Kupavna, Moscow region

Russian Federation

М. V. Bidevkina

Scientifi c Research Institute of Disinfectology of Rospotrebnadzor

Email: bidevkinamv@niid.ru

Bidevkina Marina Vasil’evna

117246, Moscow

Russian Federation

I. A. Bobrineva

All-Union Scientifi c Center for the Safety of Biologically Active Substances

Email: ural955@mail.ru

Bobrineva Irina Alekseevna

142450, Staraya Kupavna, Moscow region

Russian Federation

I. N. Razumnaya

All-Union Scientifi c Center for the Safety of Biologically Active Substances

Email: irina.r.3@mail.ru

Razumnaja Irina Nikolaevna

142450, Staraya Kupavna, Moscow region

Russian Federation

E. A. Fedorova

All-Union Scientifi c Center for the Safety of Biologically Active Substances

Email: emfed@mail.ru

Fedorova Emma Alexeеvna

142450, Staraya Kupavna, Moscow region

Russian Federation

A. Yu. Savchenko

Scientifi c Center of Biomedical Technologies of the Federal Medical Biological Agency

Email: alursav@mail.ru

Savchenko Аlla Jur’evna

143442, Moscow region

Russian Federation

G. V. Ramenskaya

I.M. Sechenov First Moscow State Medical University, RF Ministry of Health

Email: ramenskaia@mail.ru

Ramenskaya Galina Vladislavovna

119991, Moscow

Russian Federation

I. A. Pozharnov

AstraZeneca Industries LLC

Email: pozharnov@mail.ru

Pozharnov Igor Anatol’evich

249006, Kaluga region, Borovsky district, Dobrino village

Russian Federation

References

  1. Burchinsky S.G. Problem of safety in the strategy of pharmacotherapy with atypical neuroleptics. Neuro News: Psychoneurology and neuropsychiatry. 2010; 5 (24). Available at: https:// neuronews.com.ua/ru/issuearticle-337/Problema-bezopasnostiv-strategii-farmakoterapii-atipichnymineyroleptikami#gsc.tab=0. Date of access 08.08.2019 (in Russian).
  2. Maksimov V.I. Quetiapine and its place in the treatment of various diseases among the atypical psicoticos. Modern therapy of mental disorders. 2009, (2): 24-30 (in Russian).
  3. Davydov A.T., Petrova N.N., Agishev V.G. Role and place of atypical antipsychotic drugs in psychiatric practice (current state of the problem). Reviews of clinical pharmacology and drug therapy. 2005, 4 (1): 38-48 (in Russian).
  4. Mazo G.E., Ivanov M.V., Chomsky A.N., Lukmanova K.A. Risk of metabolic disorders in patients with schizophrenia when using atypical antipsychotics (review of literature data). Modern therapy of mental disorders. 2008, (1): 15-19 (in Russian).
  5. http://www.scribd.com/doc/3553710/ SEROQUEL-quetiapine-fumarate-ProductMonograph-for-Canada. Date of Revision: May 21 2008. Date of access 08.08.2019 (in Russian).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Golubeva M.I., Bidevkina М.V., Bobrineva I.A., Razumnaya I.N., Fedorova E.A., Savchenko A.Y., Ramenskaya G.V., Pozharnov I.A.


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 81728 от 11 декабря 2013.